Temporal trends in cause of death among Swedish and US men with prostate cancer
- PMID: 22835388
- PMCID: PMC3529593
- DOI: 10.1093/jnci/djs299
Temporal trends in cause of death among Swedish and US men with prostate cancer
Abstract
Background: A growing proportion of men diagnosed with localized prostate cancer detected through prostate-specific antigen testing are dying from causes other than prostate cancer. Temporal trends in specific causes of death among prostate cancer patients have not been well described.
Methods: We analyzed causes of death among all incident prostate cancer cases recorded in the nationwide Swedish Cancer Registry (1961-2008; n = 210 112) and in the US Surveillance, Epidemiology, and End Results Program (1973-2008; n = 490 341). We calculated the cumulative incidence of death due to seven selected causes that accounted for more than 80% of the reported deaths (including ischemic heart disease and non-prostate cancer) and analyzed mortality trends by calendar year and age at diagnosis and length of follow-up.
Results: During follow-up through 2008, prostate cancer accounted for 52% of all reported deaths in Sweden and 30% of reported deaths in the United States among men with prostate cancer; however, only 35% of Swedish men and 16% of US men diagnosed with prostate cancer died from this disease. In both populations, the cumulative incidence of prostate cancer-specific death declined during follow-up, while the cumulative incidences of death from ischemic heart disease and non-prostate cancer remained constant. The 5-year cumulative incidence of death from prostate cancer among all men was 29% in Sweden and 11% in the United States.
Conclusions: In Sweden and the United States, men diagnosed with prostate cancer are less likely to die from prostate cancer than from another cause. Because many of these other causes of death are preventable through changes in lifestyle, interventions that target lifestyle factors should be integrated into prostate cancer management.
Figures
Comment in
-
Prostate cancer: Proponents of PSA screening boosted by new study.Nat Rev Urol. 2012 Oct;9(10):543. doi: 10.1038/nrurol.2012.169. Epub 2012 Aug 21. Nat Rev Urol. 2012. PMID: 22907388 No abstract available.
Similar articles
-
Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.J Natl Cancer Inst. 1999 Jun 16;91(12):1025-32. doi: 10.1093/jnci/91.12.1025. J Natl Cancer Inst. 1999. PMID: 10379965
-
Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.J Natl Cancer Inst. 2010 Jul 7;102(13):950-8. doi: 10.1093/jnci/djq154. Epub 2010 Jun 18. J Natl Cancer Inst. 2010. PMID: 20562373 Free PMC article.
-
What do prostate cancer patients die of?Oncologist. 2011;16(2):175-81. doi: 10.1634/theoncologist.2010-0338. Epub 2011 Jan 21. Oncologist. 2011. PMID: 21257717 Free PMC article.
-
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. doi: 10.1093/jnci/djg040. J Natl Cancer Inst. 2003. PMID: 12953083 Review.
-
Prostate cancer in young men: an important clinical entity.Nat Rev Urol. 2014 Jun;11(6):317-23. doi: 10.1038/nrurol.2014.91. Epub 2014 May 13. Nat Rev Urol. 2014. PMID: 24818853 Free PMC article. Review.
Cited by
-
Coronary Microvascular Dysfunction in Men with Prostate Cancer Receiving Androgen-Deprivation Therapy.Clin Genitourin Cancer. 2024 Aug;22(4):102107. doi: 10.1016/j.clgc.2024.102107. Epub 2024 May 1. Clin Genitourin Cancer. 2024. PMID: 38788549 No abstract available.
-
Age-related Disparities in Pan-Cancer Mortality and Causes of Death: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data.J Cancer. 2024 Jan 21;15(6):1613-1623. doi: 10.7150/jca.91758. eCollection 2024. J Cancer. 2024. PMID: 38370383 Free PMC article.
-
Association between Statin Use and Clinical Outcomes in Patients with De Novo Metastatic Prostate Cancer: A Propensity Score-weighted Analysis.World J Mens Health. 2024 Jul;42(3):630-637. doi: 10.5534/wjmh.230155. Epub 2024 Jan 2. World J Mens Health. 2024. PMID: 38164036 Free PMC article.
-
Cardiologist-Performed Baseline Evaluation with an Assessment of Coronary Status for Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Impact on Newly Diagnosed Coronary Artery Disease.Cancers (Basel). 2023 Aug 17;15(16):4157. doi: 10.3390/cancers15164157. Cancers (Basel). 2023. PMID: 37627185 Free PMC article.
-
Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies.Medicina (Kaunas). 2023 Mar 29;59(4):681. doi: 10.3390/medicina59040681. Medicina (Kaunas). 2023. PMID: 37109639 Free PMC article. Clinical Trial.
References
-
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69 90 - PubMed
-
- Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981 990 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
